Anixa Biosciences is trading at $3.64 (+9.64%) after the company announced that IP Australia issued a Notice of Acceptance for a new patent protecting its breast cancer vaccine technology.
- The patent covers a novel vaccine approach designed to immunize against alpha-lactalbumin to prevent the emergence of triple-negative breast cancer.
- This intellectual property milestone, initially announced on July 14, has served as a primary catalyst for the stock's recent upward momentum.
- The technology is being developed in partnership with the Cleveland Clinic, and the Australian acceptance strengthens the company's global patent portfolio for its oncology pipeline.